加载中
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
前收盘价
US$13.065
+US$0.375 · +2.96%
盘中时间采用ET。市场数据可能有所延迟。
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
日内区间
当前US$13.065
52周区间
当前US$13.065
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
买入
估值
85
深度低估
情绪
70
看涨
风险
42
风险偏高
动量
69
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
日内区间
当前US$13.065
52周区间
当前US$13.065
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 5.68亿 USD | 5.73亿 USD | 5.12亿 USD | 5.12亿 USD | 4.31亿 USD |
| 销货成本 | 1.86亿 USD | 1.85亿 USD | 1.84亿 USD | 1.81亿 USD | 1.28亿 USD |
| 毛利 | 3.82亿 USD | 3.88亿 USD | 3.28亿 USD | 3.31亿 USD | 3.03亿 USD |
| 研究与开发 | 1211.3万 USD | 1363.9万 USD | 1344.6万 USD | 2385.4万 USD | 1903.9万 USD |
| 销售、一般及管理费用 | 3.12亿 USD | 3.27亿 USD | 3.04亿 USD | 3.32亿 USD | 2.54亿 USD |
| 营业费用 | 3.24亿 USD | 4亿 USD | 4.1亿 USD | 4.98亿 USD | 2.91亿 USD |
| 利息支出 | 2648.6万 USD | 3879.2万 USD | 4067.6万 USD | 1202.1万 USD | 111.2万 USD |
| 折旧和摊销 | 4701.1万 USD | 4955.5万 USD | 5736.5万 USD | 5539.8万 USD | 3487.5万 USD |
| 营业利润 | 5854.7万 USD | −1197.9万 USD | −8172.5万 USD | −1.67亿 USD | 1206.1万 USD |
| 净利润 | 2273.2万 USD | −3354.2万 USD | −1.56亿 USD | −1.59亿 USD | 1937.5万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
报告持有此股票敞口的交易所交易基金。
Avantis U.S. Small Cap Value ETFAVUV2274.33万0.07%308.51亿 USD0.25%US$119.64-0.41%
iShares Russell 2000 ETFIWM1611.4万0.02%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Morningstar Total Stock Market ETFVTI1588.42万0.00%2.3万亿 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF743.35万0.01%954亿 USD0.05%US$235+0.80%
Dimensional - US Small Cap ETFDFAS565.71万0.02%338.69亿 USD0.31%US$78.35+0.32%
iShares Russell 2000 Growth ETFIWO558.65万0.04%139.17亿 USD0.24%US$356.78+0.94%
Fidelity Enhanced Small Cap ETFFESM406.13万0.06%64.1亿 USD0.28%US$45.46+0.46%
Vanguard Russell 2000 ETFVTWO377.88万0.02%180亿 USD0.06%US$112.66+0.50%Avantis U.S. Small Cap Value ETFAVUViShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFDimensional - US Small Cap ETFDFASiShares Russell 2000 Growth ETFIWOFidelity Enhanced Small Cap ETFFESMVanguard Russell 2000 ETFVTWOAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
